Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
|Articles|August 1, 2002
Supplements and Featured Publications
- Measuring Persistency with Drug Therapy in Glaucoma Management
- Volume 8
- Issue 10 Suppl
Population-Based Persistency Rates for Topical Glaucoma Medications Measured with Pharmacy Claims Data
Advertisement
Articles in this issue
Advertisement
Related to this article
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
NPC researchers examined questions about how these policies could affect patients, pharmacies, and providers.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
A historical review traces Sjögren disease from its early descriptions to the use of salivary gland ultrasound in diagnosis.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5